Cyclopeptide mushroom poisoning: A retrospective series of 204 patients.
Amanita phalloides poisoning
acute liver failure
amatoxins
cyclopeptide mushroom
mushroom poisoning
poison control centres
severity factor
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
26
01
2023
received:
16
11
2022
accepted:
08
03
2023
medline:
12
5
2023
pubmed:
14
3
2023
entrez:
13
3
2023
Statut:
ppublish
Résumé
Cyclopeptide mushroom poisoning is responsible for 90%-95% of deaths from macrofungi ingestion. The main objectives of this study are to describe cases of cyclopeptide mushroom poisoning and to determine risk factors that may influence the severity/mortality of poisoned patients. We included all cases of amatoxin toxicity reported to two French Poison Centers from 2013 through 2019. We compared the severity with the Poison Severity Score (PSS) and the outcomes of patients using simple logistic regression and multinomial logistic regression. We included 204 cases of amatoxin toxicity. More than three-quarters developed an increase in AST and/or ALT (78.1%), and over half developed a decrease in prothrombin ratio (<70%: 53%) and/or Factor V (<70%: 54%). One-third developed an acute renal injury (AKI). Twelve patients (5.9%) developed post-poisoning sequelae (persistent kidney injury more than 1 month after ingestion and liver transplant). Five patients (2.5%) received a liver transplant, and nine died (4.4%). The mean time to onset of digestive disorders was shorter in PSS2 and PSS3-4 patients (10.9 ± 3.9/11.3 ± 6.3 h) than in PSS1 patients (14 ± 6.5 h; p < 0.05). Patients who died or developed post-poisoning sequelae had more frequent cardiovascular comorbidities compared with recovered patients (60.0% versus 29.5%; p < 0.01).
Substances chimiques
Peptides, Cyclic
0
Poisons
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-542Informations de copyright
© 2023 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.
Références
Mengs U, Torsten Pohl R, Mitchell T. Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. CPB. 2012;13(10):1964-1970.
Sinno-Tellier S, Bruneau C, Daoudi J, Greillet C, Verrier A, Bloch J. Surveillance nationale des intoxications alimentaires par des champignons: bilan des cas rapportés au réseau des centres antipoison de 2010 à 2017 en France métropolitaine/National surveillance of food poisoning by mushrooms: cases reported to the network of poison control centres from 2010 to 2017. Bull Epidémiol Hebdomad. 2019;33:666-678.
Enjalbert F, Rapior S, Nouguier-Soulé J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol: Clin Toxicol. 2002;40(6):715-757.
Courtecuisse R, Duhem B. Champignons de France et d'Europe. Delachaux et Niestlé. 2013. 543 p; (Guide Delachaux)
Vetter J. Toxins of Amanita phalloides. Toxicon. 1998;36(1):13-24.
Karlson-Stiber C, Persson H. Cytotoxic fungi-an overview. Toxicon. 2003;42(4):339-349.
Diaz JH. Amatoxin-containing mushroom poisonings: species, toxidromes, treatments, and outcomes. Wild Environ Med. 2018;29(1):111-118.
Garcia J, Costa VM, Carvalho ATP, et al. A breakthrough on Amanita phalloides poisoning: an effective antidotal effect by polymyxin B. Arch Toxicol. 2015;89(12):2305-2323.
Wienland T, Faulstich H. Fifty years of amanitin. Experientia. 1991;47(11-12):1186-1193.
Hoffman RS, Howland MA, Lewin NA, et al. 120-Mushrooms. In: Goldfrank's Toxicologic Emergencies. Tenth ed. New York: McGraw-Hill Education; 2015:1500-1514.
Broussard CN, Aggarwal A, Lacey SR, et al. Mushroom poisoning-from diarrhea to liver transplantation. Am J Gastroenterol. 2001;96(11):3195-3198.
Le Roux G, Sinno-Tellier S, Puskarczyk E, Labadie M, von Fabeck K, Pélissier F, et al. Poisoning during the COVID-19 outbreak and lockdown: retrospective analysis of exposures reported to French poison control centres. Clin Toxicol. 2021;59(9):832-9.
Persson HE, Sjöberg GK, Haines JA, de Garbino JP. Poisoning severity score: grading of acute poisoning. J Toxicol: Clin Toxicol. 1998;36(3):205-213.
International Society of Nephrology. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-141.
Roberts DM, Hall MJ, Falkland MM, Strasser SI, Buckley NA. Amanita phalloides poisoning and treatment with silibinin in the Australian Capital Territory and New South Wales. Med J Aust. 2013;198(1):43-47.
Escudié L, Francoz C, Vinel JP, et al. Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol. 2007;46(3):466-473.
Giannini L, Vannacci A, Missanelli A, et al. Amatoxin poisoning: a 15-year retrospective analysis and follow-up evaluation of 105 patients. Clin Toxicol. 2007;45(5):539-542.
Ganzert M, Felgenhauer N, Zilker T. Indication of liver transplantation following amatoxin intoxication. J Hepatol. 2005;42(2):202-209.
Pereira LM, Langley PG, Hayllar KM, Tredger JM, Williams R. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut. 1992;33(1):98-102.
Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clin Toxicol. 2009;47(2):81-88.
Liu J, Chen Y, Gao Y, et al. N-acetylcysteine as a treatment for amatoxin poisoning: a systematic review. Clin Toxicol. 2020;1-8.
Poucheret P, Fons F, Doré JC, Michelot D, Rapior S. Amatoxin poisoning treatment decision-making: pharmaco-therapeutic clinical strategy assessment using multidimensional multivariate statistic analysis. Toxicon. 2010;55(7):1338-1345.
Connors NJ, Hoffman RS, Gosselin S. Just the facts: management of cyclopeptide mushroom ingestion. CJEM. 2020;1-4.
Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Human Toxicol. 1983;2(2):183-195.
Floersheim GL. Treatment of human amatoxin mushroom poisoning: myths and advances in therapy. Med Toxicol. 1987;2(1):1-9.
Floersheim GL, Weber O, Tschumi P, Ulbrich M. Amanita phalloides: clinical poisening with amanita phalloides: pronostic factors and therapeutic measures. Schweiz Med. 1982;112(34):1164-1177.
Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-2063.
De Olano J, Wang JJ, Villeneuve E, et al. Current fatality rate of suspected cyclopeptide mushroom poisoning in the United States. Clin Toxicol. 2020;1-4.
Garcia J, Costa VM, Carvalho A, et al. Amanita phalloides poisoning: mechanisms of toxicity and treatment. Food Chem Toxicol. 2015;86:41-55.
Fineschi V, Di Paolo M, Centini F. Histological criteria for diagnosis of Amanita phalloides poisoning. J Forensic Sci. 1996;41(3):429-432.
Ginès P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol. 1999;10(8):1833-1839.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
Blei AT, Cordoba J. The practice parameters committee of the American College of Gastroenterology. Hepatic Encephal. 2001;96(7):9